Power up? Tirasemtiv may increase the power generated from fast skeletal muscle according to SUNY Medicine's Jeremy Shefner MD. Courtesy of Nature Publishing Group. All Rights Reserved.
Cytokinetics’ potential muscle booster tirasemtiv (CK-357) appears to be safe and tolerated. But riluzole dosages need to be reduced 50% due to the drug’s ability to block riluzole breakdown according to phase IIa clinical trial results presented by State University of New York Medical University’s Jeremy Shefner MD PhD. “The evidence thus far supports the further evaluation of tirasemtiv,” says Shefner.
A phase IIB 20-week randomized, double-blind placebo-controlled clinical trial is now recruiting. 400 people are expected to participate. Sites include clinics in US and Canada.
To learn more about tirasemtiv, read CK-357, helping pALS live strong? To find out about other emerging treatments for ALS, check out our full International ALS/MND Symposium meeting report ALS Trials and Tribulations.